A Agilent Technologies Inc.

Agilent Announces Inspirational LC/TQ and LC/Q-TOF Mass Spectrometry Solutions at ASMS 2023

(NYSE: A) today announced two new liquid chromatography mass spectrometry systems (LCMS), the Agilent 6495D LC/TQ and the Agilent Revident LC/Q-TOF. Facilitating the high-end performance of the Revident LC/Q-TOF, Agilent is also announcing the new Agilent MassHunter Explorer Profiling software and the new Agilent ChemVista library manager software.

The superior Agilent is ideal for demanding and challenging targeted analysis applications requiring the highest analytical sensitivity. The 6495 LC/TQ incorporates numerous intelligence features that address the critical transition between the ‘discovery phase’ of research and the ‘translational phase’ where studying a large volume of samples is crucial for generating meaningful scientific insights. The 6495 LC/TQ instrument was built for research with production-ready robustness, ensuring increased sample measurements due to greater efficiency and reduced instrument downtime. Intelligence features also include sub-millisecond dwell times and Intelligent Reflex that provides fast, sensitive, high-quality data, while early maintenance feedback and scheduled tuning keep the LC/TQ in peak working condition.

The Agilent offers an entirely new instrument architecture coupled with instrument intelligence for maximized operation time and productivity. Revident is targeted toward food safety and environmental analysis but also has applications in other small molecule markets, from metabolomics to pharmaceuticals. Incorporating the new , untargeted analyses are simplified by allowing data exploration, including statistical analysis and identification in a single software. Tasks can be performed faster with fewer errors and less expertise without compromising quality or accuracy. Additionally, the new library manager software integrates extensive curated libraries. It enables third-party import and export into a tool that conveniently connects to MassHunter, allowing access to vast external databases for identification workflows.

“The new 6495D LC/TQ offers significant improvements in sensitivity and speed over the current 6495C, which is already a reputable high-end LC/TQ, while the Revident LC/Q-TOF is the first of a new generation of LC/Q-TOF systems,” said Sudharshana Seshadri, vice president and general manager of Agilent’s Liquid Chromatography, Mass Spectrometry, and Automation Divisions.

“This launch expands the instrument intelligence from our TQ product line to our Q-TOF. Revident also includes a novel detection system that greatly enhances spectral purity, and combined with our new MassHunter Explorer Profiling and ChemVista library manager software, the Revident LC/Q-TOF is revolutionizing our customers’ experience with LC/Q-TOF—providing the highest, yet relevant, performance for meaningful scientific insights,” Seshadri added.

Agilent is a leading solution provider of proven, robust, and reliable mass spectrometry technologies to a range of segments and a wide array of applications in the bio/pharma, life science research, food, and environmental markets. These new technological capabilities enable Agilent’s customers to increase data quality and interpretation while reducing the time and human attention required—more easily adapting to ever-changing market needs.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.85 billion in fiscal 2022 and employs 18,000 people worldwide. Information about Agilent is available at . To receive the latest Agilent news, please subscribe to the Agilent . Follow Agilent on and .

EN
05/06/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Agilent Technologies Inc.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

 PRESS RELEASE

Agilent xCELLigence RTCA Instrumentation Applied in Recent FDA Approva...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) is pleased to announce its role in supporting Autolus Therapeutics’ , a recently approved CAR T therapy. Agilent's advanced cell analysis instrumentation, specifically the technology, was applied in developing and validating AUCATZYL. The xCELLigence RTCA technology supported the development and implementation of the potency assay. By providing precise and reliable cell analysis solutions, Agilent assisted Autolus in achieving the high standards required for FDA approval. Dr. Xiaobo Wang, Vice President and General Manager of the Cell Functio...

 PRESS RELEASE

CORRECTING and REPLACING Agilent to Showcase Next-Generation Digital P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Please replace the release with the following corrected version due to multiple revisions to the fifth paragraph. The updated release reads: AGILENT TO SHOWCASE NEXT-GENERATION DIGITAL PATHOLOGY SOLUTIONS AT USCAP 2025 (NYSE: A) is excited to announce its participation at the upcoming , which will be held March 22-27, 2025, in Boston. At the conference, Agilent will highlight innovative digital pathology solutions designed to enhance diagnostic accuracy and efficiency. In pathology, Agilent offers comprehensive tissue diagnostic solutions for analyzi...

 PRESS RELEASE

Agilent Research Catalyst Award Presented to Columbia University for P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced that has received an Agilent Research Catalyst (ARC) Award on behalf of , an internationally recognized researcher and physician-scientist specializing in bone marrow transplant (BMT) and cancer cellular immunotherapy. Dr. Muranski is the Director of Cellular Immunotherapy Laboratory at Columbia University Irving Medical Center. He is also an Assistant Professor of Medicine at Columbia University Medical Center, a principal investigator at the Columbia Center for Translational Immunology (CCTI), and a member of the Herbert Irv...

 PRESS RELEASE

Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Com...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced its kit has received two new companion diagnostic indications approvals under EU IVDR1, expanding the eligibility of treatment to early-stage non-small cell lung cancer (NSCLC) and previously untreated advanced melanoma patients. These two new indications bring the total indications launched in Europe for PD-L1 IHC 28-8 pharmDx to nine. PD-L1 IHC 28-8 pharmDx is approved for exclusive use with the advanced staining solution. Lung cancer and malignant melanoma are major healthcare concerns worldwide, with lung cancer accountin...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch